On Thursday, Progyny received an upgrade to its Relative Strength (RS) Rating, from 72 to 82.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the best-performing stocks tend to have an RS Rating of at least 80 as they launch their biggest runs.
Progyny is trying to complete a consolidation with a 26.76 entry. See if it can break out in volume at least 40% higher than normal.
Earnings grew 31% last quarter, up from 5% in the prior report. Revenue also increased, from 2% to 11%. The company is expected to report its latest results on or around May 8.
The company holds the No. 6 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Option Care Health and iRhythm Technologies are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
